Copyright
©2013 Baishideng Publishing Group Co.
World J Gastrointest Pharmacol Ther. Aug 6, 2013; 4(3): 54-60
Published online Aug 6, 2013. doi: 10.4292/wjgpt.v4.i3.54
Published online Aug 6, 2013. doi: 10.4292/wjgpt.v4.i3.54
Table 1 Baseline characteristics of patients
Baseline characteristics | ITPA polymorphism (rs1127354) | P value | |
CA/AA (n = 37) | CC (n = 83) | ||
Age (yr) | 61 ± 8 | 59 ± 11 | NS |
Gender: male/female | 18/19 | 37/46 | NS |
HCV RNA (log IU/mL) | 6.2 ± 0.6 | 5.9 ± 0.5 | NS |
Hemoglobin (g/dL) | 13.4 ± 1.5 | 13.8 ± 1.7 | NS |
WBC (× 103/μL) | 4.7 ± 1.2 | 5.0 ± 1.5 | NS |
Platelet (× 104/μL) | 18.0 ± 6.0 | 18.0 ± 7.0 | NS |
AST (IU/L) | 56.8 ± 34.9 | 58.2 ± 42.3 | NS |
ALT (IU/L) | 65.5 ± 40.0 | 68.4 ± 56.8 | NS |
GGT (IU/L) | 56.1 ± 52.3 | 55.3 ± 49.4 | NS |
AFP (ng/mL) | 5.3 ± 4.0 | 24.2 ± 61.8 | NS |
Staging: F1,2/F3,4 | 19/16 | 49/27 | NS |
IL28B: TT/TG + GG | 29/8 | 53/30 | NS |
-
Citation: Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, Nishiura A, Kohjima M, Yoshimoto T, Fukuizumi K, Nakashima M, Kato M, Kotoh K, Nakamuta M, Enjoji M. Association of
ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy. World J Gastrointest Pharmacol Ther 2013; 4(3): 54-60 - URL: https://www.wjgnet.com/2150-5349/full/v4/i3/54.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v4.i3.54